elife:三大**医学期刊随机对照试验分析:近400项研究结论被推翻,心血管疾病常见

2019-06-16 xujing 文韬 中国循环杂志

据一项针对三大主流期刊——美国医学协会杂志(JAMA)、柳叶刀(Lancet)和新英格兰医学杂志(NEJM)上15年来3017项随机对照试验的分析显示,近400种公认的医疗措施研究有效,但后来结论反而被推翻。

哈佛大学校长曾说,你们今天所学的医学知识中,有一半在十年后都会被认为不正确,关键是,你不知道是哪一半错的。

据一项针对三大主流期刊——美国医学协会杂志(JAMA)、柳叶刀(Lancet)和新英格兰医学杂志(NEJM)上15年来3017项随机对照试验的分析显示,近400种公认的医疗措施研究有效,但后来结论反而被推翻。

该研究调查的是,与之前的做法或更低标准的治疗相比,通过随机对照试验发现的医疗措施并没有更好,英文名称叫医疗逆转(medical reversals)。

研究者分析了2003~2017年JAMA和Lancet以及2011~2017年NEJM中的3017项随机对照研究。

作者称,在美国2013~2015年间的医疗支出增长了20%,找到和废弃昂贵而无效(或可能有害)的医疗措施尤为重要。

研究发现,在3017项随机对照研究中,有396种医疗措施被证实无效。

其中针对心血管病的治疗最常见,占20%,其次是公共卫生/预防医学(12%)和重症监护(11%)。就干预类型而言,药物是最常见的(33%),其次是手术(20%)和维生素和/或补充剂(13%)。

在心血管方面,值得注意的有以下几项:

充血性心力衰竭和肺动脉导管插入术有效性的评估研究:ESCAPE试验.JAMA

评论:肺动脉导管检查是一种诊断血液动力学监测工具,但不是治疗。我们的审查得出结论,使用肺动脉导管检并未降低死亡率,ICU或住院时间,也没有减少重症监护费用。

体外和非体外循环冠状动脉旁路移植术后的五年结果.2017.NEJM

非体外循环或体外循环冠状动脉旁路移植术后的五年结果.2016.NEJM

评论:1、非体外循环冠状动脉旁路移植术随访≥3年时死亡率过高以及反复血运重建风险增加。

2、根据目前的证据,体外循环搭桥应继续作为标准治疗。但是,当主动脉插管和体外循环有禁忌症时,非体外循环搭桥可能是可接受的。

在手术后心脏骤停后复苏期间手动胸部按压与使用自动胸部按压设备.JAMA

评论:不支持对心脏骤停患者广泛使用机械装置进行胸部按压。

研究者强调,希望研究结果有助于医生进行批判性评估,并要求进行高质量的研究。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1987250, encodeId=cb24198e25063, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Oct 28 01:52:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973070, encodeId=779519e307022, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Mar 20 05:52:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775464, encodeId=73521e75464e8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Jan 29 16:52:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068597, encodeId=d933206859e3e, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Apr 24 04:52:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296226, encodeId=8ce01296226a2, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498582, encodeId=58891498582bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513916, encodeId=c93f1513916bf, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367912, encodeId=c8ab36e9121b, content=说明研究偏倚大, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jun 17 19:17:27 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1987250, encodeId=cb24198e25063, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Oct 28 01:52:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973070, encodeId=779519e307022, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Mar 20 05:52:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775464, encodeId=73521e75464e8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Jan 29 16:52:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068597, encodeId=d933206859e3e, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Apr 24 04:52:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296226, encodeId=8ce01296226a2, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498582, encodeId=58891498582bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513916, encodeId=c93f1513916bf, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367912, encodeId=c8ab36e9121b, content=说明研究偏倚大, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jun 17 19:17:27 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
    2020-03-20 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=1987250, encodeId=cb24198e25063, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Oct 28 01:52:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973070, encodeId=779519e307022, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Mar 20 05:52:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775464, encodeId=73521e75464e8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Jan 29 16:52:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068597, encodeId=d933206859e3e, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Apr 24 04:52:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296226, encodeId=8ce01296226a2, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498582, encodeId=58891498582bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513916, encodeId=c93f1513916bf, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367912, encodeId=c8ab36e9121b, content=说明研究偏倚大, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jun 17 19:17:27 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
    2020-01-29 amyloid
  4. [GetPortalCommentsPageByObjectIdResponse(id=1987250, encodeId=cb24198e25063, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Oct 28 01:52:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973070, encodeId=779519e307022, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Mar 20 05:52:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775464, encodeId=73521e75464e8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Jan 29 16:52:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068597, encodeId=d933206859e3e, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Apr 24 04:52:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296226, encodeId=8ce01296226a2, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498582, encodeId=58891498582bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513916, encodeId=c93f1513916bf, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367912, encodeId=c8ab36e9121b, content=说明研究偏倚大, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jun 17 19:17:27 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
    2020-04-24 clmlylxy
  5. [GetPortalCommentsPageByObjectIdResponse(id=1987250, encodeId=cb24198e25063, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Oct 28 01:52:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973070, encodeId=779519e307022, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Mar 20 05:52:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775464, encodeId=73521e75464e8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Jan 29 16:52:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068597, encodeId=d933206859e3e, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Apr 24 04:52:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296226, encodeId=8ce01296226a2, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498582, encodeId=58891498582bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513916, encodeId=c93f1513916bf, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367912, encodeId=c8ab36e9121b, content=说明研究偏倚大, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jun 17 19:17:27 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1987250, encodeId=cb24198e25063, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Oct 28 01:52:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973070, encodeId=779519e307022, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Mar 20 05:52:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775464, encodeId=73521e75464e8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Jan 29 16:52:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068597, encodeId=d933206859e3e, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Apr 24 04:52:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296226, encodeId=8ce01296226a2, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498582, encodeId=58891498582bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513916, encodeId=c93f1513916bf, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367912, encodeId=c8ab36e9121b, content=说明研究偏倚大, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jun 17 19:17:27 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1987250, encodeId=cb24198e25063, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Oct 28 01:52:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973070, encodeId=779519e307022, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Mar 20 05:52:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775464, encodeId=73521e75464e8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Jan 29 16:52:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068597, encodeId=d933206859e3e, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Apr 24 04:52:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296226, encodeId=8ce01296226a2, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498582, encodeId=58891498582bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513916, encodeId=c93f1513916bf, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367912, encodeId=c8ab36e9121b, content=说明研究偏倚大, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jun 17 19:17:27 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1987250, encodeId=cb24198e25063, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Oct 28 01:52:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973070, encodeId=779519e307022, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Mar 20 05:52:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775464, encodeId=73521e75464e8, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Jan 29 16:52:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068597, encodeId=d933206859e3e, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Apr 24 04:52:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296226, encodeId=8ce01296226a2, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498582, encodeId=58891498582bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513916, encodeId=c93f1513916bf, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jun 18 07:52:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367912, encodeId=c8ab36e9121b, content=说明研究偏倚大, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jun 17 19:17:27 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
    2019-06-17 lovetcm

    说明研究偏倚大

    0

相关资讯

BMJ:RR值过大或过小,是否有必要行进一步试验?

调查随机试验中非常大的效果(VLE;定义为RR值为≤0.2或≥5)能都作为经验标志物,不再需要随后的试验。因此我们对已发表的随机试验数据进行了荟萃流行病学评估。数据来源于Cochrane系统评价数据库(2010年,7期),以后随后更新到2015年12期的大规模临床试验。3082篇综述涉及了85 002次森林图,只有44(0.05%)符合纳入标准。指数试验一般是小规模的,样本量中位数为99(中位数事

中药复方临床随机对照试验报告规范2017: CONSORT声明的扩展、说明与详述(附全文下载)

2017年6月27日是一个值得纪念的日子。中医方剂随机对照试验报告国际标准当日通过美国《内科学年鉴》正式向全球发布,以简体中文、繁体中文、英文三种文字同期发表,并配发编者社论。该标准历时十年余,由中国、加拿大、英国学者组成的国际核心团队共同完成,包括香港浸会大学协理副校长、中医药学院临床部主任、我分会副会长卞兆祥教授,四川大学华西医院、我分会顾问李幼平教授、吴泰相副教授,北京中医药大学东直门医院、

PLoS One:荟萃分析显示中药可治疗阿司匹林抵抗

背景:评估中草药(CHM)治疗阿司匹林抵抗(AR)的有效性和安全性。方法:系统性搜索7个电子数据库中评估CHM治疗AR的研究。两位作者独立的筛选数据,使用Cochrane风险偏倚工具评估研究的方法学的质量。采用RevMan 5.3软件进行数据分析。结果: 18个随机对照试验(RCT)涉及1460例受试者。15篇RCT报道,二磷酸腺苷(ADP)所致的血小板聚集率(PAR)降低有显著性差异,11例报道

J Child Psychol Psychiatry:维生素D补充剂可改善自闭症儿童的症状与体征

自闭症谱系障碍(ASD)是一种常见的发育障碍性疾病,其特征的社会交往能力、语言及非语言交流能力的丧失,兴趣与活动单一刻板。既往研究发现自闭症儿童维生素D缺乏;然而,缺乏关于ASD儿童维生素D补充剂的随机对照试验。本研究旨在探究维生素D补充剂对ASD儿童主要症状的影响。采用随机双盲对照临床试验(RCT)设计,纳入109名ASD儿童(85名男孩和24名女孩;年龄为3-10岁)。将ASD患儿随机分组,分

CTS全国呼吸病学学术会议:杨媛华:CTEPH靶向治疗-药物选择与疗效分析

在中华医学会呼吸病学年会-2017第十八次全国呼吸病学学术会议上,首都医科大学附属北京朝阳医院杨媛华教授总结了目前已知的CTEPH(慢性阻塞性肺动脉高压)靶向药物RCT研究,对CTEPH患者靶向治疗进行了完整的回顾和总结。

大型随机对照试验:精准流行病学研究的典范与陷阱

唐金陵, 杨祖耀, 毛琛. 大型随机对照试验:精准流行病学研究的典范与陷阱[J]. 中华流行病学杂志, 2017, 38(10): 1299-1304 现代流行病学是医学应用型研究的方法论,是在人群中定量地研究有关健康、疾病和医疗服务实践问题一般规律的科学和艺术。流行病学研究是与实验室基础研究分庭抗礼的两大医学研究阵营之一,可以用来研究疾病的病因和危险因素、疾病诊断的准确性、疾病负担、疾